Gainesville, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology firm committed to developing transformative medicines through cutting-edge scientific research, today announced a significant milestone in its quest to address neurodegenerative diseases. The European Patent Office has issued a notice of decision to grant the company’s European patent application No. 19805439.7
Cyclo Therapeutics Achieves European Patent Approval for Innovative Alzheimers Treatment, Signaling a New Era in N...
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Sources for this article: Based on Cyclo Therapeutics Inc ’s official statement and CSIMarket.com Customer Analytics Research for Cyclo Therapeutics Inc
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments